NANO-X IMAGING LTD (NNOX) Stock Price & How to Invest

Nano-X Imaging Ltd is a medical-imaging technology company, headquartered in Israel, developing and commercializing a new approach to X-ray imaging. Its core innovation is a digital, semiconductor-based X-ray source (a cold-cathode, MEMS-style emitter) that the company positions as a lower-cost, more compact alternative to the traditional hot-filament X-ray tubes used across the industry. That source powers the Nanox.ARC and Nanox.ARC X, multi-source digital tomosynthesis systems that produce 3D-style tomographic images and have received FDA 510(k) clearance for a range of musculoskeletal and other indications. In February 2026 the company also received FDA clearance for TAP2D, a cloud-enabled feature that generates a 2D image from a single 3D tomosynthesis scan.

Beyond hardware, Nano-X runs two supporting businesses: an AI segment (Nanox.AI, built partly on its Zebra Medical Vision acquisition) that develops algorithms to flag findings in imaging studies, and a teleradiology service that connects imaging facilities with remote radiologists. These already-revenue-generating services, together with early ARC deployments, drove Q1 2026 revenue of about $4.3 million, up year over year but still very small relative to the company's spending. Nano-X is not profitable and burns cash: it reported roughly $44.2 million of cash and equivalents as of March 31, 2026, down from about $60 million at the end of 2025, with negative operating cash flow of about $14 million in the quarter. The company has restructured its US go-to-market around partnerships and distributors, signing agreements such as a deal with Howard Technology Solutions to deploy hundreds of Nanox.ARC systems over several years, but its guidance has been volatile as commercialization timelines shift. The investment case rests on whether Nano-X can convert its technology and partnerships into meaningful, recurring, cash-generating deployment at scale before it needs to raise more capital.

The dominant risk is that Nano-X is early-commercial and unprofitable, with tiny revenue relative to its spending and ongoing cash burn, so it may need to raise additional capital that could dilute existing shareholders. Commercialization has repeatedly taken longer than hoped, and its revenue guidance has been volatile, including guidance changes tied to shifting deployment timelines. The technology, while novel, must prove durable, cost-effective, and clinically accepted against entrenched incumbents with vastly larger scale and installed bases. Regulatory, reimbursement, manufacturing, and service-network hurdles are significant barriers. The stock has a history of sharp price swings and has drawn skepticism from short sellers questioning the technology and timeline. Any funding round, clearance delay, or partnership setback can move the shares materially, and there is real risk the company does not reach self-sustaining scale.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NANO-X IMAGING LTD's investor relations page or your broker.

• Q1 2026 revenue: about $4.3 million, up year over year but still very small
• Profitability: not profitable; the company operates at a loss and burns cash
• Cash position: about $44.2 million as of March 31, 2026, down from roughly $60 million at year-end 2025
• Operating cash flow (Q1 2026): roughly negative $14 million in the quarter
• Revenue mix: driven by teleradiology and health-IT services plus early Nanox.ARC deployments
• Guidance: commercialization timelines have shifted and revenue guidance has been volatile; treat any outlook cautiously

Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Nano-X has minimal revenue and no profits, traditional earnings multiples are not meaningful, and the stock is valued largely on the perceived potential of its technology and partnerships. The most important numbers to watch are cash on hand versus quarterly burn (which together imply how long the company can operate before needing to raise money) and the pace of actual system installations, not any single revenue print.

There are three common ways to get NNOX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NNOX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where NNOX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Nano-X is a speculative, early-commercial medical-imaging story: a novel X-ray source and FDA-cleared Nanox.ARC systems plus AI and teleradiology arms, but tiny revenue, ongoing cash burn, and dilution risk. It rewards successful commercialization and can fall hard on delays or funding needs.